allisartan + benazepril

Allisartan + benazepril is a combination therapy comprising allisartan isoproxil, a selective angiotensin II receptor blocker (ARB), and benazepril, an angiotensin-converting enzyme (ACE) inhibitor. This combination is designed to provide a comprehensive dual blockade of the renin-angiotensin-aldosterone system (RAAS). Allisartan isoproxil is a prodrug developed in China that is metabolized into the active compound EXP3174, which selectively antagonizes the angiotensin II type 1 (AT1) receptor. Benazepril inhibits the ACE enzyme, thereby reducing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This therapeutic approach is primarily investigated for its efficacy in reducing proteinuria and slowing the progression of chronic kidney disease (CKD). Clinical research, including Phase 4 trials, has been conducted by The First Affiliated Hospital, College of Medicine, Zhejiang University to evaluate the safety and renal outcomes of this dual regimen compared to monotherapy.

Other names

allisartan isoproxil + benazeprilallisartan isoproxil + benazepril hydrochloride